Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Cash from Operations (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Cash from Operations for 7 consecutive years, with 27599000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 24.79% to 27599000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 149246000.0 through Dec 2025, up 25.49% year-over-year, with the annual reading at 149246000.0 for FY2025, 25.49% up from the prior year.
  • Cash from Operations hit 27599000.0 in Q4 2025 for Allogene Therapeutics, up from 29688000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 27599000.0 in Q4 2025 to a low of 68237000.0 in Q1 2022.
  • Historically, Cash from Operations has averaged 49630500.0 across 5 years, with a median of 49103000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 355.5% in 2021 and later skyrocketed 38.62% in 2025.
  • Year by year, Cash from Operations stood at 45436000.0 in 2021, then plummeted by 36.67% to 62096000.0 in 2022, then increased by 13.51% to 53707000.0 in 2023, then soared by 31.67% to 36698000.0 in 2024, then rose by 24.79% to 27599000.0 in 2025.
  • Business Quant data shows Cash from Operations for ALLO at 27599000.0 in Q4 2025, 29688000.0 in Q3 2025, and 39030000.0 in Q2 2025.